London, UK: At the annual conference of cancer specialists in Chicago, promising clinical trial data was unveiled, demonstrating that a daily pill can reduce the risk of death by 51 percent in patients with a specific type of lung cancer. The drug, osimertinib (marketed as Tagrisso), developed by pharmaceutical group AstraZeneca, significantly improved survival rates for patients with non-small cell lung cancer who had undergone surgical tumor removal.

The clinical trial involved over 680 participants from more than 20 countries, all in the early stages of the disease. Half of the patients were administered osimertinib, while the other half received a placebo. After five years, it was found that 88 percent of those treated with the drug were still alive, compared to 78 percent of those who received the placebo.

These results are particularly significant considering that lung cancer is responsible for the highest number of cancer-related deaths globally, with approximately 1.8 million fatalities each year. Osimertinib specifically targets a type of mutation on the epidermal growth factor receptor (EGFR), which affects a significant portion of lung cancer patients.

The drug’s ability to prevent the spread of cancer to other parts of the body, such as the brain, liver, and bones, was highlighted by researchers. Mr. Roy Herbst of Yale University, who presented the findings, described the data as “impressive.”

The use of osimertinib marks a major step toward personalized therapy for early-stage lung cancer patients, moving away from a one-size-fits-all approach. However, doctors emphasize the importance of screening patients to determine if they possess the EGFR mutation before prescribing the treatment.

While the drug has already been authorized in numerous countries for various indications and has been administered to around 700,000 individuals, its approval for early-stage lung cancer in the United States was contingent upon the data presented at the conference, which showcased improved overall survival rates. Osimertinib does come with side effects such as fatigue, skin rashes, and diarrhea. Nonetheless, the positive outcomes of the clinical trial offer renewed hope for patients with non-small cell lung cancer, encouraging a shift toward targeted treatments based on individual characteristics and mutations.

WORLD ROUNDUP: Saudi Arabia to reduce July oil output by 1mn barrels per Day